Stock Performance and Market Context
On 27 Feb 2026, Trident Texofab Ltd opened sharply lower at Rs.75.05, down 5.00% from the previous close, and remained at this level throughout the trading session. This price represents the lowest level the stock has traded at in the past year, a stark contrast to its 52-week high of Rs.379. The stock has been on a consecutive losing streak for 21 trading days, resulting in a cumulative return decline of -65.8% over this period.
In comparison, the Sensex index, after a flat opening with a minor dip of -28.13 points, fell by -427.15 points to close at 81,793.33, down 0.55%. While the Sensex is trading below its 50-day moving average, it remains above its 200-day moving average, indicating some underlying market resilience. Trident Texofab, however, is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — underscoring the stock’s weak momentum.
Over the last year, Trident Texofab has delivered a negative return of -58.51%, significantly underperforming the Sensex’s positive 9.62% return. This underperformance extends to the BSE500 index as well, with the stock lagging over the past three years, one year, and three months.
Financial Metrics and Fundamental Assessment
The company’s financial profile reveals several areas of concern. Trident Texofab’s long-term fundamental strength is considered weak, with an average Return on Capital Employed (ROCE) of 6.88%. This figure is below industry averages and indicates limited efficiency in generating returns from its capital base. The company’s ability to service its debt is also constrained, with a high Debt to EBITDA ratio of 6.83 times, signalling elevated leverage and potential strain on cash flows.
Recent quarterly results for December 2025 showed net sales at Rs.25.74 crores, the lowest recorded in recent periods, reflecting subdued revenue generation. Despite this, the company’s profits have risen by 122.5% over the past year, a notable increase that contrasts with the stock’s price performance. The PEG ratio stands at 0.7, suggesting that the stock’s valuation is relatively low compared to its earnings growth.
Transformation in full progress! This Micro Cap from Auto Ancillary just achieved sustainable profitability after tough times. Be early to witness this powerful comeback story!
- - Sustainable profitability reached
- - Post-turnaround strength
- - Comeback story unfolding
Valuation and Market Sentiment
Despite the weak price performance, Trident Texofab’s valuation metrics suggest some degree of attractiveness. The company’s ROCE of 7.4% paired with an Enterprise Value to Capital Employed ratio of 1.7 indicates that the stock is trading at a discount relative to its peers’ historical valuations. This discount is reflective of the market’s cautious stance given the company’s financial and operational profile.
The stock’s Mojo Score is 23.0, with a Mojo Grade of Strong Sell as of 3 Feb 2026, an upgrade from the previous Sell rating. This grading reflects the company’s weak fundamentals and market performance. The Market Cap Grade is 4, indicating a relatively small market capitalisation within its sector.
Majority shareholding remains with non-institutional investors, which may influence liquidity and trading dynamics.
Considering Trident Texofab Ltd? Wait! SwitchER has found potentially better options in Garments & Apparels and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Garments & Apparels + beyond scope
- - Top-rated alternatives ready
Sector and Industry Positioning
Operating within the Garments & Apparels industry, Trident Texofab faces competitive pressures from peers and broader market trends. The sector has witnessed varied performance, with some companies maintaining stable growth while others have struggled with demand fluctuations and cost pressures. Trident Texofab’s current valuation discount relative to peers may partly reflect these sectoral dynamics alongside company-specific factors.
The stock’s underperformance relative to the sector by -5.03% on the day further emphasises the challenges it faces in regaining investor confidence and market momentum.
Summary of Key Metrics
To summarise, the stock’s key data points as of 27 Feb 2026 are:
- New 52-week low price: Rs.75.05
- Day’s low and opening price: Rs.75.05 (down 5.00%)
- Consecutive losing days: 21
- 21-day return: -65.8%
- 1-year return: -58.51%
- 52-week high: Rs.379
- Mojo Score: 23.0 (Strong Sell)
- Debt to EBITDA ratio: 6.83 times
- Average ROCE: 6.88%
- Net sales (Dec 2025 quarter): Rs.25.74 crores
- Profit growth (1 year): +122.5%
- PEG ratio: 0.7
These figures collectively illustrate the stock’s current valuation challenges and financial profile, which have contributed to its recent price decline and 52-week low.
Conclusion
Trident Texofab Ltd’s fall to Rs.75.05 marks a significant milestone in its recent price trajectory, reflecting a combination of subdued sales, elevated leverage, and weak returns on capital. While the stock trades at a valuation discount relative to peers, its prolonged downtrend and underperformance against market benchmarks highlight ongoing concerns. The company’s financial metrics and market positioning continue to be closely monitored by market participants as it navigates this challenging phase.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
